[96a5a0]: / output / allTrials / identified / NCT05058560_identified.json

Download this file

591 lines (591 with data), 24.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
{
"info": {
"nct_id": "NCT05058560",
"official_title": "Tislelizumab in Addition to Bronchial Arterial Chemoembolization in Patients With Non-Small-Cell Lung Cancer -- A Single-arm Phase II Trial",
"inclusion_criteria": "1. Patient age between 18 and 75\n2. Signed Informed Consent Form.\n3. Confirmed TNM stage is III-Ⅳ of NSCLC ,and failed, refused or assessed ineligible to receive conventional treatments (surgery, chemoradiotherapy, Chemotherapy);\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n5. Adequate hematologic and end-organ function.\n6. Expected life span > 3 months.\n7. Be able to provide fresh or archival tumor tissues for PD-L1 expression in tumor cells\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "1. Prior therapies of docetaxel or treatment targeting PD-1, PD-L1 or CTLA-4.\n2. Prior therapies of interventional therapy (I seeds implantation, Ablation, BACE).\n3. Harboring EGFR sensitizing mutation or ALK gene translocation\n4. History of interstitial lung disease, non-infectious pneumonitis or participants with significantly impaired pulmonary function, or who require supplemental oxygen at baseline.\n5. With uncontrollable pleural effusion, pericardial effusion, or clinically significant ascites requiring interventional treatment.\n6. Symptomatic central nervous system metastasis\n7. Known HIV infection, participants with untreated chronic hepatitis B, active vaccination treatment.\n8. Prior allogeneic stem cell transplantation or organ transplantation\n9. Active autoimmune diseases or history of autoimmune diseases that may relapse.\n10. With conditions requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications\n11. Known to be hypersensitive to contrast agent;\n12. Pregnant or breastfeeding women;\n13. Other protocol defined Inclusion/Exclusion criteria may apply",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Patient age between 18 and 75",
"criterions": [
{
"exact_snippets": "Patient age between 18 and 75",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 75,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "2. Signed Informed Consent Form.",
"criterions": [
{
"exact_snippets": "Signed Informed Consent Form",
"criterion": "informed consent form",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "3. Confirmed TNM stage is III-Ⅳ of NSCLC ,and failed, refused or assessed ineligible to receive conventional treatments (surgery, chemoradiotherapy, Chemotherapy);",
"criterions": [
{
"exact_snippets": "Confirmed TNM stage is III-Ⅳ of NSCLC",
"criterion": "TNM stage of NSCLC",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"III",
"IV"
]
}
]
},
{
"exact_snippets": "failed, refused or assessed ineligible to receive conventional treatments (surgery, chemoradiotherapy, Chemotherapy)",
"criterion": "eligibility for conventional treatments",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": false
}
]
}
]
},
{
"line": "4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "5. Adequate hematologic and end-organ function.",
"criterions": [
{
"exact_snippets": "Adequate hematologic ... function.",
"criterion": "hematologic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate ... end-organ function.",
"criterion": "end-organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "6. Expected life span > 3 months.",
"criterions": [
{
"exact_snippets": "Expected life span > 3 months",
"criterion": "expected life span",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "7. Be able to provide fresh or archival tumor tissues for PD-L1 expression in tumor cells",
"criterions": [
{
"exact_snippets": "fresh or archival tumor tissues",
"criterion": "tumor tissues",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
},
{
"exact_snippets": "PD-L1 expression in tumor cells",
"criterion": "PD-L1 expression",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Prior therapies of docetaxel or treatment targeting PD-1, PD-L1 or CTLA-4.",
"criterions": [
{
"exact_snippets": "Prior therapies of docetaxel",
"criterion": "prior therapy",
"requirements": [
{
"requirement_type": "drug",
"expected_value": "docetaxel"
}
]
},
{
"exact_snippets": "treatment targeting PD-1",
"criterion": "prior therapy",
"requirements": [
{
"requirement_type": "target",
"expected_value": "PD-1"
}
]
},
{
"exact_snippets": "treatment targeting ... PD-L1",
"criterion": "prior therapy",
"requirements": [
{
"requirement_type": "target",
"expected_value": "PD-L1"
}
]
},
{
"exact_snippets": "treatment targeting ... CTLA-4",
"criterion": "prior therapy",
"requirements": [
{
"requirement_type": "target",
"expected_value": "CTLA-4"
}
]
}
]
},
{
"line": "2. Prior therapies of interventional therapy (I seeds implantation, Ablation, BACE).",
"criterions": [
{
"exact_snippets": "Prior therapies of interventional therapy (I seeds implantation, Ablation, BACE)",
"criterion": "prior interventional therapies",
"requirements": [
{
"requirement_type": "types",
"expected_value": [
"I seeds implantation",
"Ablation",
"BACE"
]
}
]
}
]
},
{
"line": "3. Harboring EGFR sensitizing mutation or ALK gene translocation",
"criterions": [
{
"exact_snippets": "Harboring EGFR sensitizing mutation",
"criterion": "EGFR sensitizing mutation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "ALK gene translocation",
"criterion": "ALK gene translocation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. History of interstitial lung disease, non-infectious pneumonitis or participants with significantly impaired pulmonary function, or who require supplemental oxygen at baseline.",
"criterions": [
{
"exact_snippets": "History of interstitial lung disease",
"criterion": "interstitial lung disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "non-infectious pneumonitis",
"criterion": "non-infectious pneumonitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "significantly impaired pulmonary function",
"criterion": "pulmonary function",
"requirements": [
{
"requirement_type": "impairment",
"expected_value": "significantly impaired"
}
]
},
{
"exact_snippets": "require supplemental oxygen at baseline",
"criterion": "supplemental oxygen requirement",
"requirements": [
{
"requirement_type": "requirement",
"expected_value": true
}
]
}
]
},
{
"line": "5. With uncontrollable pleural effusion, pericardial effusion, or clinically significant ascites requiring interventional treatment.",
"criterions": [
{
"exact_snippets": "uncontrollable pleural effusion",
"criterion": "pleural effusion",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrollable"
}
]
},
{
"exact_snippets": "uncontrollable ... pericardial effusion",
"criterion": "pericardial effusion",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrollable"
}
]
},
{
"exact_snippets": "clinically significant ascites requiring interventional treatment",
"criterion": "ascites",
"requirements": [
{
"requirement_type": "clinical significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "treatment requirement",
"expected_value": "interventional treatment"
}
]
}
]
},
{
"line": "6. Symptomatic central nervous system metastasis",
"criterions": [
{
"exact_snippets": "Symptomatic central nervous system metastasis",
"criterion": "central nervous system metastasis",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
}
]
}
]
},
{
"line": "7. Known HIV infection, participants with untreated chronic hepatitis B, active vaccination treatment.",
"criterions": [
{
"exact_snippets": "Known HIV infection",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "untreated chronic hepatitis B",
"criterion": "chronic hepatitis B",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "untreated"
}
]
},
{
"exact_snippets": "active vaccination treatment",
"criterion": "vaccination treatment",
"requirements": [
{
"requirement_type": "status",
"expected_value": "active"
}
]
}
]
},
{
"line": "9. Active autoimmune diseases or history of autoimmune diseases that may relapse.",
"criterions": [
{
"exact_snippets": "Active autoimmune diseases",
"criterion": "autoimmune diseases",
"requirements": [
{
"requirement_type": "status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "history of autoimmune diseases that may relapse",
"criterion": "autoimmune diseases",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "relapse potential",
"expected_value": true
}
]
}
]
},
{
"line": "10. With conditions requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications",
"criterions": [
{
"exact_snippets": "conditions requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent)",
"criterion": "systemic treatment with corticosteroids",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "mg daily prednisone or equivalent"
}
}
]
},
{
"exact_snippets": "conditions requiring systemic treatment with ... other immunosuppressive medications",
"criterion": "systemic treatment with immunosuppressive medications",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "11. Known to be hypersensitive to contrast agent;",
"criterions": [
{
"exact_snippets": "Known to be hypersensitive to contrast agent",
"criterion": "hypersensitivity to contrast agent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "12. Pregnant or breastfeeding women;",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "13. Other protocol defined Inclusion/Exclusion criteria may apply",
"criterions": [
{
"exact_snippets": "Other protocol defined Inclusion/Exclusion criteria",
"criterion": "protocol defined criteria",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "8. Prior allogeneic stem cell transplantation or organ transplantation",
"criterions": [
{
"exact_snippets": "Prior allogeneic stem cell transplantation",
"criterion": "allogeneic stem cell transplantation",
"requirements": [
{
"requirement_type": "prior occurrence",
"expected_value": true
}
]
},
{
"exact_snippets": "prior ... organ transplantation",
"criterion": "organ transplantation",
"requirements": [
{
"requirement_type": "prior occurrence",
"expected_value": true
}
]
}
]
}
],
"failed_miscellaneous": []
}